Issued on behalf of Aleen Inc.
VANCOUVER – USA News Group News Commentary – The race to integrate artificial intelligence into healthcare has reached record investment levels, with AI-powered healthcare and biotech startups raising $10.7 billion in 2025, already surpassing last year’s full-year total[1]. Major health systems are now deploying AI solutions across clinical documentation, patient engagement, and data analytics at seven times the adoption rate of just one year ago[2]. This acceleration is creating significant opportunities for companies building AI-driven wellness platforms, precision medicine tools, and digital health infrastructure. Among those positioned to benefit are Aleen Inc. (CSE: ALEN-U), OneMedNet Corporation (NASDAQ: ONMD), SOPHiA GENETICS (NASDAQ: SOPH), Astrana Health, Inc. (NASDAQ: ASTH), and Doximity, Inc. (NYSE: DOCS).
Industry analysts project the global digital health and wellness market will surge from $607 billion in 2025 to $3.57 trillion by 2034, representing annual growth exceeding 21%[3]. With hospitals and healthcare providers prioritizing AI investments that deliver measurable returns on clinical efficiency and patient outcomes, companies offering data-driven wellness insights and intelligent analytics are entering a period of exceptional demand[4].
Aleen Inc. (CSE: ALEN-U), a Canadian digital wellness company, has announced the development of a personal account system designed to redefine how individuals interact with their wellness data. The upcoming personal account will serve as an intuitive hub where users can seamlessly upload, manage, and visualize their well-being information.
“This is about giving people ownership of their wellness journey,” said Oleksandr Luzin, Director of Aleen Inc. “We’re creating a system that turns information into confidence — and privacy into empowerment.”
The company previously announced it was beginning early concept testing for smart wellness analytics, with research highlighting three recurring user expectations: clear visualization of personal wellness patterns, strong privacy safeguards and control over shared information, and simple, non-medical interpretation of structured inputs.
“Our current focus is on understanding how an analytical tool can responsibly support everyday well-being — while staying entirely outside the realm of diagnostic or medical functions,” said Anastasiia Kalashnik, PR Specialist of Aleen Inc. “We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions.”
Based in Ontario, Aleen Inc. went public in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The company operates in a rapidly expanding market, with the global digital wellness sector currently valued at approximately $12.87 billion in 2025 and projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand.
The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.’s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.
Looking ahead to 2026, Aleen Inc. plans to launch the personal user accounts currently in development alongside the smart analytics features being tested. To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment, with plans to allocate 35% toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion including mobile apps and specialized modules for corporate wellness programs.
With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities.
CONTINUED… Read this and more news for Aleen Inc. at:
OneMedNet Corporation (NASDAQ: ONMD) has accelerated its subscription revenue strategy through significant network expansion, growing clinical exams by 37% to exceed 186 million and increasing unique de-identified patient records by 38% to surpass 47 million. The company added approximately 380 provider sites over three months, bringing its total network to more than 2,130 healthcare sites and cementing its position as one of the largest continuously refreshed, regulatory-grade Real-World Data networks globally.
“Our subscription model is now gaining significant momentum,” said Aaron Green, President & CEO of OneMedNet. “In the $60 billion Real-World Evidence market, pharmaceutical, life-science, and AI customers subscribe to our platform for ongoing access to the precise, diverse, and longitudinal cohorts they require. Each incremental expansion of sites, encounters, and clinical exams materially enhances the depth, specificity, and value of those data feeds.”
The company’s iRWD™ platform serves drugmakers, medical device pioneers, and AI visionaries across rare diseases, oncology, cardiology, and other therapeutic areas. OneMedNet‘s proprietary AI anonymization technology also extends beyond healthcare to industries including finance, retail, and telecom.
SOPHiA GENETICS (NASDAQ: SOPH) has announced a collaboration with Complete Genomics to integrate sequencing and AI analytics, launching MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics‘ DNBSEQ-T1+ sequencing platform. The partnership aims to broaden access to precision oncology testing by providing clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path to comprehensive genomic profiling.
“This collaboration underscores SOPHiA GENETICS‘ commitment to broadening access to data-driven medicine,” said Ross Muken, President of SOPHiA GENETICS. “Partnering with Complete Genomics to streamline use of MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions.”
Joint evaluation demonstrated highly concordant variant calls and allele frequencies compared with equivalent sequencing systems while achieving lower background noise and reduced turnaround time. The SOPHiA DDM™ platform leverages AI to compute, standardize, and analyze healthcare data across a broad global network of hospital, laboratory, and biopharma institutions.
Astrana Health, Inc. (NASDAQ: ASTH) reported third quarter 2025 results with total revenue of $956.0 million, up 100% year-over-year, and adjusted EBITDA of $68.5 million, up 52% from the prior year period. The company completed its acquisition of Prospect Health on July 1, 2025, with standalone third quarter performance exceeding expectations and integration progressing well across multiple states.
“Astrana delivered solid third quarter results and demonstrated strong momentum in our first quarter of combined operations with Prospect Health,” said Brandon Sim, President and CEO of Astrana Health. “Prospect’s performance exceeded our expectations, and integration is progressing well, expanding our scale, capabilities, and physician reach across key markets. We continue to execute with discipline and focus on building a more coordinated, high-quality, and accessible care delivery platform for the long term.”
The provider-centric, technology-powered healthcare company now supports more than 20,000 providers and over 1.6 million patients in value-based care arrangements. Astrana announced updated full-year 2025 guidance projecting total revenue between $3.1 billion and $3.18 billion with adjusted EBITDA between $200 million and $210 million.
Doximity, Inc. (NYSE: DOCS) announced fiscal 2026 second quarter financial results with total revenue of $168.5 million, up 23% year-over-year, and adjusted EBITDA of $100.8 million, representing a margin of 59.8%. The leading digital platform for U.S. medical professionals reported operating cash flow of $93.9 million and free cash flow of $91.6 million, both up 37% year-over-year.
“Our platform continues to grow with new AI tools to save physicians’ time,” said Jeff Tangney, co-founder and CEO of Doximity. “In Q2, a record 650,000 prescribers used our workflow tools to better serve their patients, while our AI Scribe and DoxGPT users grew over 50% from the prior quarter.”
The company’s network includes more than 80% of U.S. physicians across all specialties and practice areas, with new AI-powered clinical reference and search capabilities helping doctors access trusted, peer-reviewed information. Doximity provided guidance for fiscal third quarter revenue between $180 million and $181 million, with full-year revenue projected between $640 million and $646 million.
Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
USA NEWS GROUP
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval.
—
SOURCES:
- https://www.techloy.com/why-are-ai-healthcare-and-biotech-startups-are-pulling-in-record-funding-in-2025/
- https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/
- https://www.towardshealthcare.com/insights/digital-health-and-wellness-market-sizing
- https://www.mckinsey.com/industries/healthcare/our-insights/the-coming-evolution-of-healthcare-ai-toward-a-modular-architecture
Please insert a hyperlink to the press release here when it goes live.
